Physician profile
Sameh S Labib
NPI 1982771705
$18,772.28
in general payments reported to CMS, 2019-2025
68 companies · $2,404 in 2025
The $2,404 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,908 · 2020: $1,353 · 2021: $2,322 · 2022: $3,199 · 2023: $3,314 · 2024: $3,272 · 2025: $2,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,764 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,764.42 |
| Education | $226.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,991.26 | 2021-2025 | |
| Biogen, INC. | $1,445.92 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Emd Serono, INC. | $1,381.58 | 2019-2025 | Mavenclad |
| Ucb, INC. | $1,192.48 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,122.20 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $722.05 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Eisai INC. | $676.95 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $656.69 | 2019-2022 | |
| Neurelis, INC. | $597.14 | 2020-2025 | Valtoco |
| Kyowa Kirin, INC. | $565.72 | 2021-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $449.66 | 2019-2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $439.11 | 2019-2025 | Ultomiris, Soliris, Koselugo |
| Argenx US, INC. | $403.59 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alnylam Pharmaceuticals INC. | $399.56 | 2019-2024 | Onpattro |
| Lilly USA, LLC | $360.65 | 2019-2025 | Emgality, Reyvow, Amyvid |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Labib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.